The Wall Street Journal: FDA rejects Eli Lilly’s proposed Alzheimer’s treatment, says more data needed

The setback could delay a potential commercial introduction of the highly anticipated drug by at least several months, if the Food and Drug Administration eventually decides to approve it.

Previous post MarketWatch First Take: Netflix co-founder Reed Hastings showed Silicon Valley the proper leadership path
Next post Dow Jones Newswires: U.K. consumer confidence unexpectedly deteriorates in January